The Global Hyperkalemia Treatment Market Analysis, Regional, Trends, Opportunity, Forecast Period

 

Globally, the rise in the geriatric population is causing an increase in the prevalence of acute and chronic hyperkalemia. Because of the aging population and developments in medical technology, the prevalence of heart failure and chronic kidney disease is expected to rise, putting a larger number of patients at risk for hyperkalemia. The number of elderly people, those aged 60 and above, is anticipated to more than double by 2050 and more than triple by 2100, according to data from the World Population Prospects: The 2017 Revision, growing from 962 million in 2017 to 2.1 billion in 2050 and 3.1 billion in 2100.

Worldwide, hyperkalemia has been documented in about 5% of the general population. According to the National Kidney Foundation, hyperkalemia can be as high as 20% in heart failure patients with chronic kidney disease (CKD), and it is linked to an elevated risk of mortality and significant adverse cardiovascular events. Between 2013 and 2016, the overall prevalence of CKD (stages 1-5) among the adult general population in the United States was 14.8 percent, according to the United States Renal Data System (USRDS) (2018).

Reduced mineralocorticoid activity decreased distal Na+ supply, and CCD dysfunction may all contribute to chronic hyperkalemia caused by poor renal excretion. When considered separately, these pathophysiologic mechanisms do not usually result in persistent hyperkalemia, but their consequences are clinically substantial when combined. One of the most common illness problems among individuals with CKD is chronic hyperkalemia. According to the National Kidney Foundation, approximately 37 million people in the United States have CKD, and over 80% of them are unaware of their condition. ​

In addition, the treatment of persistent hyperkalemia necessitates confirmation, intensified laboratory surveillance, dietary review, and counseling, a review of drugs (prescription, over-the-counter, and herbal), and, if necessary, the use of a potassium-lowering medication and/or a diuretic. If you're looking for a uniqueThe proportion of people with CKDs rises as kidney function declines; it ranges from 5% to 50% in patients. Over the projected period, the chronic hyperkalemia segment of the market examined is expected to increase. This is projected to be propelled by an increase in the prevalence of chronic hyperkalemia, as well as an increase in the elderly population and related illnesses. ​

The hyperkalemia treatment market is consolidated, with only a few companies dominating it. With the release of Veltassa at the beginning of 2016, the hyperkalemia market saw significant changes. Veltassa was the first novel medicine for the treatment of hyperkalemia in over 50 years. AstraZeneca PLC, Ardelyx, Vifor Pharma Management Ltd, Sanofi SA, and Perrigo Company are a few significant market participants.